Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023)

Historic Cash from Investing Activities for Marker Therapeutics (MRKR) over the last 6 years, with Q2 2023 value amounting to $18.8 million.

  • Marker Therapeutics' Cash from Investing Activities rose 92854.11% to $18.8 million in Q2 2023 from the same period last year, while for Dec 2023 it was $18.7 million, marking a year-over-year increase of 47742.38%. This contributed to the annual value of $18.7 million for FY2023, which is 47742.38% up from last year.
  • According to the latest figures from Q2 2023, Marker Therapeutics' Cash from Investing Activities is $18.8 million, which was up 92854.11% from -$112608.0 recorded in Q1 2023.
  • In the past 5 years, Marker Therapeutics' Cash from Investing Activities registered a high of $18.8 million during Q2 2023, and its lowest value of -$4.1 million during Q4 2020.
  • Over the past 5 years, Marker Therapeutics' median Cash from Investing Activities value was -$286484.5 (recorded in 2019), while the average stood at $53332.5.
  • In the last 5 years, Marker Therapeutics' Cash from Investing Activities crashed by 3177809.83% in 2020 and then skyrocketed by 92854.11% in 2023.
  • Over the past 5 years, Marker Therapeutics' Cash from Investing Activities (Quarter) stood at -$12862.0 in 2019, then plummeted by 31778.1% to -$4.1 million in 2020, then surged by 91.47% to -$349843.0 in 2021, then skyrocketed by 63.6% to -$127342.0 in 2022, then surged by 14845.12% to $18.8 million in 2023.
  • Its last three reported values are $18.8 million in Q2 2023, -$112608.0 for Q1 2023, and -$127342.0 during Q4 2022.